SPECT/CT在177Lu-PSMA-617诊疗一体化中的作用:基于病例的缓解与进展模式综述
本文为基于病例的综述,探讨治疗后SPECT/CT显像在转移性去势抵抗性前列腺癌(mCRPC)患者177Lu-PSMA治疗监测中的作用,将治疗反应分为良好缓解、进展和混合缓解模式,以改善图像解读并指导治疗调整。
要点
- 治疗后SPECT/CT是监测177Lu-PSMA治疗反应的新兴工具,可追踪治疗中的功能变化。
- 定量SPECT分析可预测患者结局,但定性评估在临床环境中更实用且省时。
- 基于SPECT/CT的治疗反应分为良好缓解、进展和混合缓解模式,以指导治疗调整。
核心结论
- 基于治疗后SPECT/CT的治疗反应可分为良好缓解、进展和混合缓解模式,有助于改善解读并指导治疗调整,以优化mCRPC的Lu-PSMA治疗管理。
研究设计与样本
- 基于病例的综述,依据治疗后SPECT/CT显像评估治疗反应。
主要发现
- 177Lu-PSMA在mCRPC患者中已显示可改善无进展生存期和总生存期。
- 治疗后SPECT/CT显像可追踪治疗期间的功能变化。
- 定量SPECT分析可预测患者结局,而定性评估在临床环境中更实用且省时。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lutetium-177 prostate-specific membrane antigen-617 (Lu-PSMA) has demonstrated efficacy in improving progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). Post-treatment single photon emission tomography/computed tomography (SPECT/CT) imaging is an emerging tool for monitoring treatment response, enabling the tracking of functional changes during therapy. While quantitative SPECT analysis can predict patient outcomes, qualitative assessments are more practical and time-efficient in clinical settings. This case-based review examines treatment responses based on post-treatment SPECT/CT imaging, categorizing them into favorable response, progression, and mixed response patterns to improve interpretation and guide therapeutic adjustments, aiming to optimize management of mCRPC with Lu-PSMA therapy.
引用
- Ghodsi A, Demirci RA, Chen DL, et al. The Role of SPECT/CT in 177 Lu-PSMA-617 Theranostics: Case-based Review of Response and Progression Patterns. Clin Nucl Med. 2025. PMID: 40394842. doi:10.1097/RLU.0000000000005986
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。